- Open Access
Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot
Acta Neuropathologica Communications volume 2, Article number: 130 (2014)
The paraffin-embedded tissue (PET) blot technique followed by limited protease digestion has been established to detect protein aggregates in prion diseases, alpha-synucleopathies, and tauopathies. We analyzed whether the scope of the method can be extended to analyze aggregates in mouse and human tissue with amyotrophic lateral sclerosis (ALS) associated with superoxide dismutase 1 (SOD1) mutation.
Formalin-fixed and paraffin-embedded brain and spinal cord tissue from SOD1G93A mice was first analyzed for the expression of SOD1, aggregated SOD1, ubiquitin, and p62 by convential immunohistochemistry and then used to establish the PET blot technique, limited protease digest, and immunodetection of SOD1 aggregates. The method was then transferred to spinal cord from an ALS patient with SOD1E100G mutation.
Mouse and human paraffin-embedded brain and spinal cord tissue can be blotted to membranes and stained with anti-SOD1 antibodies. The SOD1 labelling is abolished after limited proteolytic digest in controls, whereas under identical conditions SOD1 aggregates are detected the SOD1G93A mouse model of ALS and in human familial ALS. The most prominent areas where aggregates could be detected are the brainstem and the anterior horn of the spinal cord.
Applicability of the PET blot technique to demonstrate SOD1 aggregates in ALS tissue associated with mutations in the SOD1 gene offers a new approach to examine potential spreading of aggregates in the course of ALS.
Neurodegenerative diseases are characterized by the accumulation of proteins with aberrant conformation in the affected tissues. Disturbances of mechanisms that normally ensure clearance of misfolded proteins have been identified to underlie or contribute the deposition. Included here are e.g. dysfunction of the chaperone machinery, failure of the proteasomal system ,, and impairment of autophagic mechanisms . Recently, it was recognized that template assisted misfolding or seeded polymerization contributes to the burden of protein aggregates in a number of proteinopathies, comparable to the propagation of conformationally changed prion protein in prion diseases ,.
Amyotrophic lateral sclerosis (ALS) is a phenotypically heterogeneous disease characterized by degeneration of upper and lower motoneurons. 90% of ALS cases are sporadic and 10% are caused by mutations in different genes. Around 20% of the familial cases are associated with mutations in the Cu/Zn superoxide dismutase 1 (SOD1) . Mutated SOD1 forms aggregates of fibrillar structure in the affected tissues , and recent data suggest that there is also a propensity for aggregation of posttranslationally modified wild type SOD1 in a subset of sporadic ALS cases . Misfolding and aggregation of SOD1 in the spinal cord and the motor cortex is also observed in mice transgenic for disease associated mutated human SOD1 representing the most established model for ALS . Neuronal inclusions are positive for ubiquitin and p62 ,.
The misfolding state depends on the mutation and on the method of detection . Some antibodies were generated and are in part commercially available which are reported to solely recognize misfolded SOD1. A way to detect misfolded proteins independently on antibodies recognizing the misfolded form is to subject tissue or homogenates from animals or humans with a proteinopathy to a limited protease digest, leading to destruction of the physiologically folded protein but leaving off the conformationally changed form(s), which afterwards can be immunodetected by non-conformation-specific antibodies. A method that was initially established for the detection of misfolded prion protein in fixed tissue from patients or animals with prion disease , is the paraffin-embedded tissue (PET) blot technique. This technique combines the advantages from highly sensitive immunohistochemistry, reveals anatomical resolution and can be performed with paraffin-embedded tissue.
Here we report on the applicability of the PET blot technique for the detection of misfolded SOD1 in paraffin-embedded tissue from ALS mice and from human fALS post-mortem tissue.
Material and methods
The principles of laboratory animal care were followed and use of the mice was performed in accordance with the national guidelines and was approved by local authorities. Male mice transgenic for human SOD1G93A (huSOD1G93A, B6.Cg-Tg[SOD1-G93A]1Gur/J; stock number 004435) were acquired from the Jackson laboratory (Ben Harbor, Maine). These transgenic mice are characterized by survival times of 128.9+/−9.1 days. By breeding with female C57Bl/6J from an in-house breed wild type mice and SOD1G93A littermates of either sex were generated for the experiments. At terminal disease state the mice used for establishment of the PET-blot were between 132 and 159 days old.
Mice at terminal disease stage were anesthetized and transcardially perfused with PBS for cryoconservation of the tissue or by PBS followed by paraformaldehyde in case of subsequent paraffin embedding as published elsewhere . Prepared were the spinal cords as well as the whole brains separated sagittally into the two hemispheres.
The study of human control tissue was performed in compliance with university ethics committee guidelines and the laws governing human tissue usage in the German federal state of Baden-Württemberg. Consent for autopsy was obtained for all patients and controls or from their next of kin. Brain tissue of the ALS case was collected by the Newcastle Brain Tissue Resource (NBTR) at Newcastle University, UK, after relevant informed consent from the donor and in accordance with Newcastle University ethics board and ethical approval awarded by The Joint Ethics Committee of Newcastle and North Tyneside Health Authority (reference: 08/H0906/136).
Two control cases were studied: 1. male, 38 years of age, head trauma, (neuropathological staging: Braak NFT 0 , Abeta phase 0 , Braak PD stage 0 ); 2. female 72 years of age, ruptured aortic aneurysm (neuropathological staging: Braak NFT I, Abeta phase 0, Braak PD stage 0.
The ALS case was a female age 48 at death who had the diagnosis 12 years before death. The mother, two uncles and a sister were also affected by ALS. Testing during lifetime revealed the E100G mutation in the SOD1 gene. Initial symptoms were cramp and muscle twitching in legs, progressing to fasciculation in upper limbs and trunk and lower limb weakness. Marked bulbar symptoms developed. There was no apparent cognitive impairment. The cause of death was cardiac arrest and asphyxia secondary to ALS (neuropathological staging: Braak stage 0, CERAD score  none, no Lewy Body pathology, no cerebral infarcts).
The spinal cords were removed in toto and fixed in a 4% aqueous solution of formaldehyde for 10–20 days prior to dissection. The dura mater of each spinal cord was then opened with a dissecting scissors and anchored bilaterally with pins to a cork board. After macroscopic inspection, tissue blocks from the cervical, thoracic, lumbar, and sacral spinal cord with the dorsal and ventral roots were made, embedded in paraffin, and sectioned at 7 μm in the transversal plane.
Paraffin-embedded tissue sections (5 μm) were dried over night at 37°C and immersed in two changes of 5 min xylene and acetone. Deparaffinized sections were rinsed with water, exposed to microwave and afterwards endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol. After 2 washes with PBS for 5 min the sections were perfused with 0.2% Triton in PBS and then blocked with 10% fetal bovine serum PBS. Subsequently, the respective primary antibody was diluted in blocking solution (polyclonal anti-human SOD1 (abcam ab52950) and anti human/mouse SOD1 antibodies (ab16831), 1:500; anti-ubiquitin, Biorad 9400–1004, 1:250, monoclonal anti-p62 (SQSTM1), abcam ab91526, 1:500) and applied over night at 4°C. After 3 washes in PBS for 5 min the sections were either incubated for 1 h at RT with goat-anti-rabbit peroxidase-coupled secondary antibody (Biorad), washed again 3 times and developed with DAB (sigma fast) for about 10 min, or incubated with biotin-coupled secondary anti-mouse antibody (Biorad), washed again and developed with ABC-kit (Pierce). Counterstaining with 100% hemalaun was followed by dehydration and mounting of the slices with entellan.
Paraffin-embedded tissue blot
Pieces of PVDF membrane (20 mm x 50 mm Fluorobind, Serva, Heidelberg, Germany) were prewetted in methanol for 10 sec followed by water. Sagittal mouse brain sections of 5 μm or transverse mouse/human spinal cord sections were cut and put into a water bath at 40°C, transferred to the prewetted membrane and dehydrated at 55°C for 2 h. Deparaffination/rehydration was carried out by two changes of 5 in: Xylene, 100% - 96% - 70% ethanol, TBS (50 mM Tris–HCl pH 7.6, 150 mM NaCl) including drying of the membrane between xylene and 100% ethanol and between 70% ethanol and TBS which avoids detaching of the membrane from the glas.
For the establishment of partial proteinase K (PK) digest a series of experiments was carried out applying 5-250 μg/ml PK for 4-21 h. 5 μg/ml PK and a digestion time of 15 h was worked out to be best: PK below 5 μg/ml or digestion times below 15 h yielded results comparable to PK-untreated PET-blots and increases in concentration or digestion times above 5 μg/ml 15 h yielded blank PET-blots. All PK digested PET blots shown were treated with 5 μg/ml PK added to digest buffer (10 mM Tris–HCl pH 7.8, 100 mM NaCl, 0.1% Brij) and incubated with the membrane in an oven at 55°C for 15 hours. After the digest the PET-Blots were washed 3 × 5 min in TBS with 0.5% Tween 20 (TBS-T).
The endogenous peroxidase was blocked at RT by incubation with 3% hydrogen peroxide for 5 min. Then the sections were washed three times with TBS-T for 5 min. Epitope retrieval was achieved by incubation of the membrane with 4 M guanidiumthiocyanat in 10 mM Tris–HCl, ph 7.8, for 15 min. After 3 washes (TBS-T 5 min) the blots were blocked (Tropix I-Block, Applied biosystems, Bedford, U.S.A) for 1 h at RT. Primary antibodies specific for human SOD1 or for mouse&human SOD1 (both from Abcam,see above)), for 14-3-3 proteins (Santa Cruz sc-629), were diluted 1:1000 in I-Block, respectively, and incubated with the blots on a rocker over night at 4°C. Biotinylated secondary antibody (Dako, Glostrup, Denmark) diluted 1:500 in I-Block was added after 3x 10 min washes with TBS-T for 1 h at RT. Excess antibody was washed out 5 times with TBS-T for 10 min. Subsequently the membranes were incubated avidin-biotinylated-complex (ABC) solution for 1.5 hours. After 5 x 10 min wash in TBS-T the blots were developed by adding 3,3' diaminobenzidine (fast DAB, Sigma, Steinheim, Germany) for 10 min. The membranes were mounted on glass slides with a 3:2 ratio of DMSO:96% ethanol.
Pictures were taken with a Zeiss Mirax digital scanning microscope, a Zeiss Axiovert 200 or Axioskop 2plus microscope, post processing was carried out using adobe photoshop.
In brain sections from end-stage SOD1G93A mice immunohistochemically (IHC) stained for human SOD1 a widespread expression of the transgene is visible with most intense staining in the brain stem, particularly in motor-associated regions of the pons and the medulla as well as in midbrain regions, e.g. substantia nigra pars compacta and the reticular nucleus (Figure 1a). A pronounced staining of the cerebellar molecular layer and a moderate staining of cerebellar nuclei can be seen. At higher magnification, the strong staining of the cytoplasm of neurons in the medulla oblongata (Figure 1d) and in the midbrain area becomes visible.
In PET-blots applying anti-human SOD1 antibody (Figure 1b) a less intense overall staining is observed which appears to be more uniformly distributed over the whole tissue compared to the IHC. Taking a closer look distinct staining becomes visible frequently localized to the edges of pathologic vacuoles as well as to the cytoplasm of neurons in both the medulla oblongata (Figure 1e) and the midbrain (not shown). When PET blots are digested with proteinase K at a concentration of 5 μg/ml for 15 h the edges of the blotted tissues are barely seen and immunopositive structures are left almost entirely in the brain stem (Figure 1c). The structures that are strongly labelled have a size of few to around 30 μm and round or (tangled) skein-like shape (Figure 1f,g). Cellular structures are mostly deleted.
In contrast, staining for endogenous murine SOD1 in PET-blots of wild type (WT) mice brain sections which appears relatively uniformly distributed over the blot with predominantly cytoplasmic staining as shown for the medulla region (Figure 1h) does not resist proteolytic digestion with 5 μg/ml protease K for 15 h (Figure 1i). PET-blots from WT mice brains were also probed with anti-human SOD1 anibodies yielding no staining (data not shown) verifying the specificity of antibody binding in analyses of transgenic tissue.
Brain areas that are strongly positive for transgenic SOD1 are frequently also positive in PK digested PET-blots. To exclude that the SOD1 labelling that can be detected after limited PK digestion is only leftover because of initially high expression levels, we did experiments applying the PET-blot technique to another highly expressed protein in the brain, the 14-3-3 protein. Without proteolysis an intense cytoplasmic staining can be seen (Figure 1j). By treatment of the PET-blot with PK staining is completely abolished in the medulla as well as in other brain regions and only faint transparent tissue derived structures are visible (Figure 1k).
The PET-blot technique can also be applied to transversal mouse spinal cord sections (HE-stained section in Figure 2a). High expression of the transgenic human SOD1 is detected by anti-human SOD1 antibodies in the cells in the grey matter (Figure 2b) and an intense staining of structures in the grey matter is even obtained after limited proteolytic digest (Figure 2c). This is in contrast to mouse WT tissue: the staining of PET- blots obtained after probing anti-mouse SOD1 antibodies (Figure 2d) is abolished by PK treatment (Figure 2e). The labelled structures in the SOD1G93A spinal cord appear skein-like or tangled (Figure 2g) as in the brain stem and can hardly be seen in conventional SOD1 immunohistochemistry (data not shown) or in PK-untreated SOD1 PET-blots (Figure 2f). Also in ubiquitin IHC (Figure 2h,i) large labelled structures are observed but less frequently and they are more difficult to recognize than in the protease treated SOD1 PET-blot.
We went then to the examination if also human post-mortem ALS tissue is suitable for the PET-blot analysis of SOD1 aggregates. In transverse spinal cord sections from an ALS patient with the SOD1E100G mutation we found by SOD1 IHC (overview in Figure 3a) expression in both neurons and glial cells in the grey matter (Figure 3d) and glial cells in the white matter (Figure 3e). In the spinal cord section of a control patient SOD1 is found in neurons of the grey matter (Figure 3f) but glial cells are largely negative. Aggregates in ALS tissue cannot be obviously seen, when SOD1 is stained. We performed IHC for ubiquitin and for p62. While the ubiquitin IHC was indistinguishable comparing ALS with control tissue (Figure 3k,l), neuropathological differences can be seen in the ALS tissue stained for p62, namely occasionally occurring aggregate-like structures (Figure 3i,j).
When human ALS spinal cord tissue is subjected to PET-blot SOD1 staining in the white and grey matter is preserved (Figure 3b,g), however aggregates become clearly visible when the blotted tissue is PK-treated before immunodetection (Figure 3c,h).
In recent years evidence accumulated that in neurodegenerative diseases, including ALS, disease progression is caused or paralleled by spreading of the disease specific respective pathological protein. Comparable to prion diseases, in which the pathological prion protein propagates by a seeding/nucleation polymerization process and is transferred from cell to cell, stereotypic spread has been observed in e.g. synucleopathies and Alzheimer’s disease -. For in vitro and in vivo studies and especially for the examination of the neuropathologically characteristic misfolded, oligomerized and aggregated proteins discrimination between normal and aberrant forms is essential.
The PET-blot approach differentiates between normal and aggregated proteins. It takes advantage of a limited protease resistance of conformationally changed proteins compared to the normal forms in tissue sections blotted onto PVDF or nitrocellulose membranes prior to immunodetection. This was first established for prion diseases and the PK resistance was attributed to the amyloid structure with high beta sheet content of the pathological prion protein . The PET-blot technique, which combines high sensitivity of detection with acceptable histological resolution, has been shown to be applicable to study aggregate distribution and follow the spreading also in synucleopathies and Alzheimer’s disease ,. This data tempted us to test if SOD1 aggregates can also be detected in PET-blots of brain sections from genetic ALS brains. Especially for the study of post-mortem paraffin-embedded human ALS brains and spinal cords collected in biobanks as well as for the longitudinal study of ALS mouse tissue the development of approaches to track aggregates during disease progression is important.
Here we show that brain and spinal cord tissue from SOD1G93A mice and from a patient with SOD1 mutation can be subjected to the PET-blot method and that aggregates resist a limited protease digest while endogenous/normal forms of SOD1 are degraded and not longer detected by conventional SOD1 antibody. Compared to IHC staining of ubiquitin and p62, both of which are published to bind SOD1 aggregates and are used to study diseased tissue -, aggregates can easier be seen and a reliable quantification seems possible.
Recently, antibodies specifically recognizing misfolded SOD1 have been developed and successfully used for examination of human and mouse ALS tissue. Some of these antibodies also react with conformationally changed post-translationally modified wild-type SOD1 forms present also in the majority of sALS cases revealing inclusions that weren’t seen formally presumably because of masking by the abundant properly folded SOD1 ,-. It has to be demonstrated if it is possible to differentiate between different misfolded SOD1 forms with the PET-blot approach, e.g. by applying a range of proteinase concentrations, however masking of aggregates by reactivity of the antibody to alternative SOD1 forms is not to be expected. Future experiments have to be conducted to analyse SOD1 aggregates by IHC with conformation dependent antibodies in order to compare the results with those that came up from PET-blots. Beyond that the analysis of PET-blots with conformation dependent antibodies will probably extent the detection potential and knowledge about the behaviour of muSOD1 aggregates during progression of disease and even of misfolded WT SOD1 in sporadic ALS.
Different mutations in the SOD1 gene can be associated with different properties of the protein with regard to hydrophobicity, di- and oligomerization, aggregation propensity, and toxicity -. Localization and tracking of mutated SOD1 offers the opportunity to examine several aspects of ALS, as selective vulnerability of specific cells, cell to cell transmission, or co-occurrence of inclusions and neurodegeneration. Exemplarily for human fALS, we analyzed fixed spinal cord tissue from a patient with the E100G mutation in the SOD1 gene. For this mutation posterior column involvement has been reported and ubiquitinated neuronal inclusions have been infrequently detected . In the spinal cord subjected to PET-blot aggregates are easily investigatable and can be localized to areas of the grey matter.
In conclusion, we established a technique for the analysis of misfolded SOD1 in familial ALS useful in aggregate detection, localization and tracking that is applicable to biobanked material. Subgroups of ALS might be identified with different propagation of conformationally changed SOD1.
Bendotti C, Marino M, Cheroni C, Fontana E, Crippa V, Poletti A, De Biasi S: Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response. Prog Neurobiol 2011, 97(2):101–126. doi:S0301–0082(11)00179–1 10.1016/j.pneurobio.2011.10.001 10.1016/j.pneurobio.2011.10.001
Cheroni C, Marino M, Tortarolo M, Veglianese P, De Biasi S, Fontana E, Zuccarello LV, Maynard CJ, Dantuma NP, Bendotti C: Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum Mol Genet 2009, 18(1):82–96. doi:ddn319 10.1093/hmg/ddn319 10.1093/hmg/ddn319
Otomo A, Pan L, Hadano S: Dysregulation of the autophagy-endolysosomal system in amyotrophic lateral sclerosis and related motor neuron diseases. Neurol Res Int 2012, 2012: 498428. doi:10.1155/2012/498428 10.1155/2012/498428
Polymenidou M, Cleveland DW: The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011, 147(3):498–508. doi:S0092–8674(11)01209–8 10.1016/j.cell.2011.10.011 10.1016/j.cell.2011.10.011
Grad LI, Yerbury JJ, Turner BJ, Guest WC, Pokrishevsky E, O'Neill MA, Yanai A, Silverman JM, Zeineddine R, Corcoran L, Kumita JR, Luheshi LM, Yousefi M, Coleman BM, Hill AF, Plotkin SS, Mackenzie IR, Cashman NR: Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc Natl Acad Sci U S A 2014, 111(9):3620–3625. doi:10.1073/pnas.1312245111 10.1073/pnas.1312245111
Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, Floeter MK, Henderson C, Lomen-Hoerth C, Macklis JD, McCluskey L, Mitsumoto H, Przedborski S, Rothstein J, Trojanowski JQ, van den Berg LH, Ringel S: Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(Suppl 1):5–18. doi:10.3109/21678421.2013.778548 10.3109/21678421.2013.778548
Bruijn LI, Miller TM, Cleveland DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004, 27: 723–749. doi:10.1146/annurev.neuro.27.070203.144244 10.1146/annurev.neuro.27.070203.144244
Kerman A, Liu HN, Croul S, Bilbao J, Rogaeva E, Zinman L, Robertson J, Chakrabartty A: Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol 2010, 119(3):335–344. doi:10.1007/s00401–010–0646–5 10.1007/s00401-010-0646-5
Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, Goolsby H, Fontaine BA, Lemay N, McKenna-Yasek D, Frosch MP, Agar JN, Julien JP, Brady ST, Brown RH Jr: Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nature neuroscience 2010, 13(11):1396–1403. doi:10.1038/nn.2660 10.1038/nn.2660
Kato S: Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol 2008, 115(1):97–114. doi:10.1007/s00401–007–0308–4 10.1007/s00401-007-0308-4
Leigh PN, Whitwell H, Garofalo O, Buller J, Swash M, Martin JE, Gallo JM, Weller RO, Anderton BH: Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 1991, 114(Pt 2):775–788. 10.1093/brain/114.2.775
Maekawa S, Leigh PN, King A, Jones E, Steele JC, Bodi I, Shaw CE, Hortobagyi T, Al-Sarraj S: TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathology 2009, 29(6):672–683. doi:NEU1029 10.1111/j.1440–1789.2009.01029.x 10.1111/j.1440-1789.2009.01029.x
Prudencio M, Borchelt DR: Superoxide dismutase 1 encoding mutations linked to ALS adopts a spectrum of misfolded states. Mol Neurodegener 2011, 6: 77. doi:1750–1326–6-77 [pii] 10.1186/1750–1326–6-77 10.1186/1750-1326-6-77
Schulz-Schaeffer WJ, Fatzer R, Vandevelde M, Kretzschmar HA: Detection of PrP(Sc) in subclinical BSE with the paraffin-embedded tissue (PET) blot. Arch Virol Suppl 2000, 16: 173–180.
Schulz-Schaeffer WJ, Tschoke S, Kranefuss N, Drose W, Hause-Reitner D, Giese A, Groschup MH, Kretzschmar HA: The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. Am J Pathol 2000, 156(1):51–56. doi:S0002–9440(10)64705–0 10.1016/S0002–9440(10)64705–0 10.1016/S0002-9440(10)64705-0
Steinacker P, Hawlik A, Lehnert S, Jahn O, Meier S, Gorz E, Braunstein KE, Krzovska M, Schwalenstocker B, Jesse S, Propper C, Bockers T, Ludolph A, Otto M: Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis. Am J Pathol 2010, 176(3):1409–1420. doi:S0002–9440(10)60452-X 10.2353/ajpath.2010.090355 10.2353/ajpath.2010.090355
Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82(4):239–259. 10.1007/BF00308809
Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58(12):1791–1800. 10.1212/WNL.58.12.1791
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24(2):197–211. 10.1016/S0197-4580(02)00065-9
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41(4):479–486. 10.1212/WNL.41.4.479
Polymenidou M, Cleveland DW: Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 2012, 209(5):889–893. doi:10.1084/jem.20120741 10.1084/jem.20120741
Guest WC, Silverman JM, Pokrishevsky E, O'Neill MA, Grad LI, Cashman NR: Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. J Toxicol Environ Health A 2011, 74(22–24):1433–1459. doi:10.1080/15287394.2011.618967 10.1080/15287394.2011.618967
Rey NL, Petit GH, Bousset L, Melki R, Brundin P: Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 2013, 126(4):555–573. doi:10.1007/s00401–013–1160–3 10.1007/s00401-013-1160-3
Jucker M, Walker LC: Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 2011, 70(4):532–540. doi:10.1002/ana.22615 10.1002/ana.22615
Kramer ML, Schulz-Schaeffer WJ: Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007, 27(6):1405–1410. doi:27/6/1405 10.1523/JNEUROSCI.4564–06.2007 10.1523/JNEUROSCI.4564-06.2007
Moh CF, Siedlak SL, Tabaton M, Perry G, Castellani RJ, Smith MA: Paraffin-embedded tissue (PET) blot method: application to Alzheimer disease. J Neurosci Methods 2010, 190(2):244–247. doi:S0165–0270(10)00269–4 10.1016/j.jneumeth.2010.05.010 10.1016/j.jneumeth.2010.05.010
Basso M, Massignan T, Samengo G, Cheroni C, De Biasi S, Salmona M, Bendotti C, Bonetto V: Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. J Biol Chem 2006, 281(44):33325–33335. doi:M603489200 10.1074/jbc.M603489200 10.1074/jbc.M603489200
Gal J, Strom AL, Kwinter DM, Kilty R, Zhang J, Shi P, Fu W, Wooten MW, Zhu H: Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism. Journal of neurochemistry 2009, 111(4):1062–1073. doi:10.1111/j.1471–4159.2009.06388.x 10.1111/j.1471-4159.2009.06388.x
Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD: Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 2001, 8(6):933–941. doi:10.1006/nbdi.2001.0443 10.1006/nbdi.2001.0443
Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, Jacobsson J, Rosquist R, Marklund SL, Brannstrom T: Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 2010, 5(7):e11552. doi:10.1371/journal.pone.0011552 10.1371/journal.pone.0011552
Broering TJ, Wang H, Boatright NK, Wang Y, Baptista K, Shayan G, Garrity KA, Kayatekin C, Bosco DA, Matthews CR, Ambrosino DM, Xu Z, Babcock GJ: Identification of human monoclonal antibodies specific for human SOD1 recognizing distinct epitopes and forms of SOD1. PloS One 2013, 8(4):e61210. doi:10.1371/journal.pone.0061210 10.1371/journal.pone.0061210
Pickles S, Destroismaisons L, Peyrard SL, Cadot S, Rouleau GA, Brown RH Jr, Julien JP, Arbour N, Vande Velde C: Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum Mol Genet 2013, 22(19):3947–3959. doi:10.1093/hmg/ddt249 10.1093/hmg/ddt249
Furukawa Y, Kaneko K, Yamanaka K, Nukina N: Mutation-dependent polymorphism of Cu, Zn-superoxide dismutase aggregates in the familial form of amyotrophic lateral sclerosis. J Biol Chem 2010, 285(29):22221–22231. doi:10.1074/jbc.M110.113597 10.1074/jbc.M110.113597
Munch C, Bertolotti A: Exposure of hydrophobic surfaces initiates aggregation of diverse ALS-causing superoxide dismutase-1 mutants. J Mol Biol 2010, 399(3):512–525. doi:10.1016/j.jmb.2010.04.019 10.1016/j.jmb.2010.04.019
Tiwari A, Hayward LJ: Mutant SOD1 instability: implications for toxicity in amyotrophic lateral sclerosis. Neurodegener Dis 2005, 2(3–4):115–127. doi:10.1159/000089616 10.1159/000089616
Ince PG, Shaw PJ, Slade JY, Jones C, Hudgson P: Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol 1996, 92(4):395–403. 10.1007/s004010050535
This work was supported by BMBF (ministry of science and technology): FTLDc, MND-net, the JNPD networks (BiomarkAPD, Sophia), and Thierry Latran foundation. We thank Kelly Del Tredici, MD, PhD (University of Ulm) for providing spinal cord tissue from control cases. We especially thank Evamaria Goerz and Stephen Meier for technical help and Dr. Thomas Ciossek (Boehringer Ingelheim).
D. R. Thal gave the following disclosures: consultant honoraria from GE Healthcare, Covance Laboratories, and Simon-Kucher & Partners, and collaboration with Novartis Pharma AG. All other authors have nothing to disclose.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Steinacker, P., Berner, C., Thal, D.R. et al. Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot. acta neuropathol commun 2, 130 (2014). https://doi.org/10.1186/s40478-014-0130-x
- Amyotrophic lateral sclerosis
- Superoxide dismutase 1
- Protein aggregates